SillaJen, Inc. (KOSDAQ:215600)
South Korea · Delayed Price · Currency is KRW 2,810.00
+120.00 (4.46%)
Nov 20, 2025, 3:30 PM KST
SillaJen Company Description
SillaJen, Inc. engages in developing technologies and products using genetic engineering in South Korea.
The company develops Pexa-Vec, which is in phase 2 clinical trial to treat renal Cell Carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors.
It also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors; and SJ-600 Series and JX-970 to treat solid tumors and is in preclinical trial.
SillaJen, Inc. was founded in 2006 and is headquartered in Seoul, South Korea.
SillaJen, Inc.
| Country | South Korea |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 37 |
| CEO | Jaekyung Kim |
Contact Details
Address: 109, Sogong-ro Seoul South Korea | |
| Phone | 82 2 368 2600 |
| Website | sillajen.com |
Stock Details
| Ticker Symbol | 215600 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| ISIN Number | KR7215600008 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jaekyung Kim | Chief Executive Officer |
| Suk Song Myung | Chief Financial Officer |